Last Updated on:
Advance Tests Introduces Non-Invasive LucentAD Complete to Improve Accessibility and Accuracy
Advance Tests has announced the launch of LucentAD in the United Kingdom, a new and innovative blood test for the . Developed by Lucent Diagnostics, a commercial brand of Quanterix Corporation, this groundbreaking test combines multiple biomarkers to accurately classify the risk of amyloid pathology associated with Alzheimer’s Disease.
The partnership between Lucent Diagnostics and Advance Tests allows for the test to be available to patients and healthcare providers in the UK, with appointments starting on December 2nd. This launch marks a significant milestone in providing accessible and accurate Alzheimer’s diagnostics in the UK.
Dr. Karan Jutlla, Head of the Centre for Applied and Inclusive Health Research at the University of Wolverhampton, said this non-invasive blood test is a game-changer for early Alzheimer’s diagnosis in the UK.
The LucentAD Complete test offers several advantages, including its availability for bookings starting now and its high accuracy of 90% in detecting amyloid pathology. Priced at £695, the test is a cost-effective alternative to PET imaging and lumbar punctures, which can be significantly more expensive. It also requires only a blood sample, making it non-invasive and eliminating the need for costly imaging procedures. This aligns with Advance Tests’ mission to make life-saving diagnostics widely accessible.
The test utilises multiple biomarkers, including p-Tau 217, to improve amyloid detection and provide conclusive results for approximately 90% of cases. It meets the performance standards set by the Global CEO Initiative on Alzheimer’s Disease and the US Alzheimer’s Association, offering a more advanced option compared to current gold standard diagnostic approaches.
The test will be available on a private basis, with appointments offered at Advance Tests’ first clinic on St Thomas Street in London. Additional clinics are planned for cities across the UK to expand patient access to this transformative diagnostic tool. Appointments can be booked directly or through healthcare providers via www.advancetests.com.
Dr. Simon Worrell, Founder and Chief Medical Officer of Advance Tests, expressed his pride in bringing LucentAD Complete to the UK and the potential it has to transform Alzheimer’s care. He also mentioned working with Quanterix to remove barriers to early diagnosis and provide timely treatment that can greatly impact patients’ lives.
Dr. Karan Jutlla, Head of the Centre for Applied and Inclusive Health Research at the University of Wolverhampton, also commented on the introduction of LucentAD Complete, stating that having access to this sophisticated, non-invasive blood test is a game-changer for early Alzheimer’s diagnosis in the UK. This test simplifies diagnostics, making it easier for more patients to access critical care, especially with new therapies for early-stage Alzheimer’s becoming available.
